Eli Lilly Announces Research and Licensing Collaboration with Avidity Biosciences to Pursue Therapeutics Targets Focused on Immunology, Eli Lilly to Pay $20M Upfront and Make a $15M Investment in Avidity
Benzinga Newsdesk